AVELUMAB MAINTENANCE EXTENDS OVERALL SURVIVAL IN ADVANCED UROTHELIAL CARCINOMA
The addition of maintenance #Avelumab ( #Bavencio ) to best supportive care extended overall survival ( OS ) for patients with previously untreated locally advanced or metastatic #urothelial #carcinoma, according to study results released by the agent’s manufacturer.
Urothelial carcinoma accounts for approximately 90% of #bladder #cancer cases. Only 5% of patients with metastatic disease survive 5 years.
XAGENA NEWS -> Il trattamento di mantenimento con Avelumab prolunga la sopravvivenza globale nel carcinoma uroteliale avanzato ( LINK:
https://xagena.it/articolo/il-trattamento-di-mantenimento-con-avelumab-prolunga-la-sopravvivenza-globale-nel-carcinoma-uroteliale-avanzato )
XAGENA IN ONCOLOGIA
A) SITI #WEB: OncologiaMedica.net - TumoriRari.net - OncoImmunoTerapia.net OncoGinecologia.net - MelanomaOnline.net
B) NEWSLETTER: https://www.xagenaweb.it/
C) ONCOHUB: https://oncohub.it/
D) ONCOPNEUMOLOGIA:
https://www.oncopneumologia.it/
E) ONCOUROLOGIA: https://oncourologia.it/
F) ONCOLOGY:
https://www.oncologyonline.net/
-